Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about GSK, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Belimumab FDA approved Jul 2017 · Benlysta |
Systemic Lupus Erythematosus | Phase 4 · NCT01632241 | Completed |
| Momelotinib FDA approved Sep 2023 · Ojjaara |
Primary Myelofibrosis | Phase 3 · NCT04173494 | Completed |
| Dostarlimab (TSR-042) FDA approved Apr 2021 · Jemperli |
Ovarian Clear Cell Carcinoma | Phase 1/2 · NCT06065462 | Recruiting |
| Standard therapy | Systemic Lupus Erythematosus | Phase 4 · NCT01632241 | Completed |
| Camlipixant | Cough | Phase 3 · NCT05600777 | Active not recruiting |
| Nab-paclitaxel | Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 · NCT02101021 | Terminated |
| Protein Phosphatase 2A Inhibitor LB-100 | Ovarian Clear Cell Carcinoma | Phase 1/2 · NCT06065462 | Recruiting |
| RPT193 | Asthma | Phase 2 · NCT05935332 | Terminated |
| HS235 | Pulmonary Hypertension | Phase 1/2 · NCT07123779 | Recruiting |
| Ozureprubart | Immune System Diseases | Phase 2 · NCT07220811 | Active not recruiting |
| DNA Interference Oligonucleotide PNT2258 | Lymphoma, Diffuse Large B-Cell | Phase 2 · NCT02226965 | Completed |
| Tivumecirnon (FLX475) | Advanced Melanoma | Phase 2 · NCT04894994 | Terminated |
| Chk1 Inhibitor SRA737 | Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL) | Phase 1/2 · NCT02797964 | Completed |
| HS135 | Heart Failure With Preserved Ejection Fraction | Phase 1 · NCT06581159 | Terminated |
| Rabeprazole | Cough | Phase 1 · NCT05899829 | Completed |
| Velzatinib (IDRX-42) | Gastrointestinal Neoplasms | Phase 1 · NCT05489237 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not GSK's own candidates): Ruxolitinib, Gemcitabine Hydrochloride, Danazol, Alitretinoin, Ipilimumab, Pembrolizumab, Bortezomib, Trametinib, Rifampin, Gemfibrozil, Dabigatran Etexilate.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
GSK holds $3B in cash and short-term investments and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GSK files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR LLC | Institution (13G, 5%+) | 234,936,061 | 5.44% | 2026-03-31 |
| Dodge & Cox Inc. | Institution (13F) | 43,183,117 | 1.00% | 2026-09-30 |
| Fisher Asset Management, LLC | Institution (13F) | 35,351,693 | 0.82% | 2026-09-30 |
| Primecap Management Company | Institution (13F) | 25,192,138 | 0.58% | 2026-09-30 |
| GSK plc 10% owner |
Insider | 18,245,691 | 0.42% | 2025-12-11 |
| Wellington Management Group, LLP | Institution (13F) | 9,650,852 | 0.22% | 2026-09-30 |
| JTC Employer Solutions Trustee Ltd. | Institution (13F) | 8,077,477 | 0.19% | 2026-09-30 |
| Morgan Stanley | Institution (13F) | 7,584,742 | 0.18% | 2026-09-30 |
| Price (T.Rowe) Associates Inc | Institution (13F) | 6,712,097 | 0.16% | 2026-09-30 |
| Goldman Sachs Group Inc | Institution (13F) | 6,021,779 | 0.14% | 2026-09-30 |
Share count 4,315,445,026 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-10-19 | Jemperli | sBLA | -3% | -0.1% | +2.5% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GSK and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →